Business Context and Reporting Period
Company: Calidi Biotherapeutics, Inc. (CLDI)
Filing Type: Form 8-K (Current Report)
Date of Report: April 19, 2024
Reporting Period: Single event date (April 19, 2024)
Business Context: The Company is an emerging growth company incorporated in Delaware, focused on biotherapeutics. This filing serves as a Regulation FD disclosure to distribute updated investor presentation slides.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of non-financial presentation materials rather than a financial results report.
Material Changes
No material changes to financial performance or operations are reported in this filing. The sole material event is the release of updated presentation slides for use with investors and analysts.
Guidance, Outlook, and Risks
- Management Commentary: The Company is furnishing updated presentation slides (Exhibit 99.1) to be used in presentations to investors and analysts.
- Legal Status of Information: The information contained in the presentation slides is "furnished" and not "filed" under Section 18 of the Exchange Act. It is not subject to the liabilities of that section and shall not be deemed incorporated by reference in any other filing.
- Outlook: No specific financial guidance or forward-looking projections are detailed in the text of this 8-K.
Investor Verification Checklist
- Review Exhibit 99.1 (Presentation Slides) attached to the filing for the actual content, data, and strategic updates intended for investors.
- Verify the legal disclaimer stating that the presentation slides are not deemed filed for liability purposes under Section 18 of the Exchange Act.
- Confirm the trading symbols (CLDI for common stock, CLDIWS for warrants) and the exchange (NYSE American LLC).
- Note that the Company is classified as an emerging growth company.